Skip to main content
Shandong Pharmaceutical Glass Co.,Ltd logo

Shandong Pharmaceutical Glass Co.,Ltd — Investor Relations & Filings

Ticker · 600529 ISIN · CNE000001BG9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2026-05-12 Notice of Dividend Amou…
Country CN China
Listing Shanghai Stock Exchange 600529

About Shandong Pharmaceutical Glass Co.,Ltd

https://en.pharmglass.com/

Shandong Pharmaceutical Glass Co., Ltd. specializes in the research, development, and manufacturing of glass packaging materials. The company’s product portfolio includes molded glass bottles, tubular glass vials, glass ampoules, and glass cartridges, alongside complementary components such as butyl rubber stoppers and aluminum-plastic caps. These products are engineered to meet international quality standards for the storage and delivery of injectable drugs, oral liquids, and various healthcare products. Utilizing advanced production technologies, the firm provides comprehensive packaging solutions to the pharmaceutical, food, and cosmetic sectors. Its operations focus on maintaining high chemical resistance and structural integrity across its glass containers to ensure product safety and stability.

Recent filings

Filing Released Lang Actions
山东省药用玻璃股份有限公司2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 88% confidence The document is an official announcement detailing the 2025 annual profit distribution (dividend) plan, including per‐share cash dividend amount, record date, ex‐dividend date, payment date, and tax treatment. This matches a Notice of Dividend Amount.
2026-05-12 Chinese
山东省药用玻璃股份有限公司关于参加2026年山东辖区上市公司投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in an online investor interaction event organized by regulatory and industry bodies. It mentions the date and time of the event and topics to be discussed, including financial performance and governance, but does not contain actual financial statements or detailed reports. The document is short (539 characters) and serves as a notice to investors about the event rather than a report or transcript of the event itself. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2026-05-07 Chinese
山东省药用玻璃股份有限公司关于马来西亚全资子公司完成注册登记的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the completion of registration of a wholly-owned subsidiary in Malaysia by Shandong Pharmaceutical Glass Co., Ltd. It includes details about the subsidiary's name, registration number, capital, and business scope. The document is short (903 characters) and serves as a formal notification of a corporate event rather than a financial report or detailed filing. It does not contain financial statements, audit information, or management discussion. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under a general regulatory announcement category about corporate structure changes but not specifically board changes or capital changes. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2026-04-24 Chinese
山东省药用玻璃股份有限公司第十一届董事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 11th Board of Directors' 8th meeting of Shandong Pharmaceutical Glass Co., Ltd. It includes details about the meeting date, attendance, and voting results. The key agenda item was the approval of the company's 2026 first quarter report, but the document itself does not contain the financial statements or substantive financial data of the report. Instead, it states that the full 2026 first quarter report is disclosed on the Shanghai Stock Exchange website. This indicates that the document is an announcement of the board meeting resolutions and the approval of the quarterly report, not the quarterly report itself. The document is also relatively short (1200 characters) and serves as a formal disclosure of board decisions. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management, including meeting resolutions.
2026-04-24 Chinese
山东省药用玻璃股份有限公司2026年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '山东省药用玻璃股份有限公司2026年第一季度报告' which translates to 'Shandong Pharmaceutical Glass Co., Ltd. 2026 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes for the first quarter of 2026. The report explicitly states it is a quarterly report and includes unaudited financial statements for the quarter ending March 31, 2026. The length of the document (13,558 characters) and the presence of comprehensive financial data confirm it is a full interim/quarterly financial report rather than a brief announcement or summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-04-24 Chinese
山东省药用玻璃股份有限公司关于2025年度“提质增效重回报”行动方案的评估报告暨2026年度行动方案的公告
Management Reports Classification · 95% confidence The document is titled as an "evaluation report" and an "action plan" for the years 2025 and 2026, issued by the board of directors of 山东省药用玻璃股份有限公司. It contains detailed assessments of the company's operational performance, investor relations, governance, and strategic plans. The content includes comprehensive management commentary on business quality, investor returns, innovation, governance, and future plans. It is not a brief announcement or a simple notice but a substantive report on management's evaluation and forward-looking action plan. There is no indication that this is a full annual report (10-K) or an interim financial report (IR) with detailed financial statements, nor is it a regulatory filing or announcement. The document fits best as a Management Report (MDA) because it provides management's detailed explanation of business trends, performance evaluation, and outlook, consistent with the MDA filing definition.
2026-04-24 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.